KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Net Margin (2016 - 2025)

Historic Net Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 35.2%.

  • Vertex Pharmaceuticals' Net Margin fell 25100.0% to 35.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.35%, marking a year-over-year increase of 358600.0%. This contributed to the annual value of 4.86% for FY2024, which is 415400.0% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Net Margin is 35.2%, which was down 25100.0% from 34.84% recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Net Margin registered a high of 42.94% during Q3 2021, and its lowest value of 135.83% during Q2 2024.
  • Moreover, its 5-year median value for Net Margin was 36.73% (2023), whereas its average is 25.48%.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -1725600bps in 2024, then surged by 1706700bps in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Margin (Quarter) stood at 37.16% in 2021, then fell by -4bps to 35.56% in 2022, then increased by 8bps to 38.48% in 2023, then dropped by -19bps to 31.35% in 2024, then grew by 12bps to 35.2% in 2025.
  • Its Net Margin stands at 35.2% for Q3 2025, versus 34.84% for Q2 2025 and 23.33% for Q1 2025.